Northwest Biotherapeutics, Inc. (NWBO) Research
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Market snapshot
- Symbol
- NWBO
- Price
- $0.19
- Day change
- -0.03%
- Market cap
- $312.2M
- P/E ratio
- -6.86x
- 52-week range
- 0.18-0.37
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Peer companies
Recent insider activity
- BOYNTON ALTON L — G-Gift (1000000 shares) on 2024-08-29
- BOSCH MARNIX L — G-Gift (3000000 shares) on 2024-08-09
- BOYNTON ALTON L — G-Gift (1000000 shares) on 2024-08-08
- MALIK NAVID — S-Sale (657895 shares) on 2024-07-26
- MALIK NAVID — S-Sale (125000 shares) on 2023-11-16
Open Northwest Biotherapeutics, Inc. (NWBO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.